Real-world outcomes of FOLFOXIRI demonstrate effective disease control in unresectable colorectal cancer, indicating potential for conversion surgery.
In Japanese practice, first-line FOLFOXIRI achieved substantial disease control and clinically meaningful survival with manageable toxicity. R0 conversion was achieved in the subset with longer survival. A conversion-oriented triplet induction strategy may be considered for rectal cancer without peritoneal metastasis, irrespective of RAS status.
No takes yet. Share an insight, caveat, or question.
Inoue et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: